SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.

Related Keywords

Angelos Stergiou ,Life Sciences Group ,Sciences Group ,Hematologic Oncology ,News ,Sls009 ,Venetoclax ,Venclexta ,Azacitidine ,Vidaza ,Acute Myeloid Leukemia ,Nct04588922 ,Asxl1 ,